Middle East and Africa Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Middle East and Africa diabetes drugs market is segmented into drugs (Insulin, Oral anti-diabetic drugs, Non-Insulin Injectable drugs, and Combination Drugs) and geography (Saudi Arabia, Iran, Egypt, Oman, South Africa, and the Rest of the Middle East and Africa). The report offers the value (in USD million) and volume (in Units million) for the above segments.

MEA Diabetes Drugs Market Size

MEA Diabetes Drugs Market Summary
Study Period: 2017- 2028
CAGR: 6.6 %

Major Players

MEA Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and it's growth?

MEA Diabetes Drugs Market Analysis

The Middle East and Africa diabetes drugs market is set to register a CAGR of 6.6% and reach a value of about USD 6.5 billion over the forecast period.

Diabetes and uncontrolled hyperglycemia were risk factors for poor outcomes in patients with COVID-19, including an increased risk of severe illness or death. Patients with diabetes who were infected with SARS-CoV-2 experienced additional stress and increased secretion of hyperglycemic hormones such as glucocorticoids and catecholamines, which resulted in elevated blood glucose, abnormal glucose variability, and diabetic complications. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control could improve outcomes and reduce the length of stay in patients with SARS-CoV-2 underlined the importance of oral anti-diabetic drugs. As diabetes was associated with both poorer clinical outcomes during the COVID-19 pandemic and an increased risk of death in such hospitalized patients, the role of glucose control was emphasized to improve the prognosis.

High levels of glucose in the blood are a defining feature of diabetes, which is a chronic condition resulting from either an inability to produce or effectively use insulin. The main types of diabetes are type-1 and type-2. Diabetic drugs are medicines developed to stabilize and control blood glucose levels in people with diabetes. Diabetic drugs are commonly used to manage diabetes. For a patient with type-1 diabetes, insulin therapy is important for replacing the insulin that the body doesn't produce. People with type-2 diabetes or gestational diabetes need pharmacotherapy if other treatments, such as lifestyle changes, are not able to keep blood glucose levels within the desired range.

The Middle East and African region witnessed an alarming increase in the prevalence of diabetes in recent years. The rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes treatment aims to maintain healthy blood glucose levels to prevent both short- and long-term complications, such as cardiovascular disease, kidney disease, blindness, and lower limb amputation. 73 million adults were living with diabetes in the IDF MENA Region, according to IDF 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region live with impaired glucose tolerance, which places them at increased risk of developing type-2 diabetes. Patients with diabetes require many corrections throughout the day to maintain normal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

MEA Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Middle East and Africa Diabetes Drugs Market is segmented into drugs (Insulin, Oral anti-diabetic drugs, Non-Insulin Injectable drugs, and Combination Drugs) and Geography (Saudi Arabia, Iran, Egypt, Oman, South Africa, and the rest of the Middle East and Africa). The report offers the value (in USD million) and volume (in Units million) for the above segments. Further, the report will cover a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.

Oral Anti-diabetic Drugs
Alpha - Glucosidase Inhibitors
Alpha - Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Saudi Arabia
South Africa
Rest of Middle East and Africa

Report scope can be customized per your requirements. Click here.

MEA Diabetes Drugs Market Trends

The Oral Anti-Diabetic Drugs Segment is expected to dominate the Middle East and Africa Diabetes Drugs Market over the forecast period

The oral anti-diabetic drugs segment is expected to dominate the Middle East and Africa diabetes drugs market and register the highest CAGR of about 7.7% over the forecast period.

Oral anti-diabetic drugs have been available internationally and are recommended for use when escalation of treatment for type-2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in the treatment of type-2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help diabetes patients keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take antidiabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

In July 2022, Zydus Lifesciences announced that it received final approval to market empagliflozin and metformin hydrochloride tablets in multiple strengths. Empagliflozin and metformin hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type-2 diabetes mellitus and established cardiovascular disease.

Governments in the ME have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Most countries have fully implemented national diabetes treatment guidelines. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. However, constant measures are being taken to minimize diabetic complications.

Owing to the rising rate of obesity, the growing genetic factors for type-2 diabetes, the increasing prevalence, and the aforementioned factors, it is likely that the market will continue to grow.

Middle East and Africa Diabetes Drugs Market, Type-2 Diabetes Population in million, 2017-2022

Saudi Arabia is expected to dominate the Middle East and African Diabetes Drugs Market over the forecast period

Saudi Arabia holds the highest market share in the Middle East and African diabetes drug markets and is also expected to register a CAGR of around 12.1% over the forecast period.

More than one in ten people in Saudi Arabia lived with diabetes, and the prevalence of the disease was expected to almost double by 2045, according to the IDF 2021 report. The IDF report mentioned that 4.27 million people in Saudi Arabia, which has a population of about 34.8 million, have diabetes, while 1.86 million people have the disease but are yet to be diagnosed. This figure is estimated to increase to 5.6 million by 2030 and further to 7.5 million by 2045.

The growing incidence, prevalence, and progressive nature of the disease have encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients suffering from type-2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes have entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2). Oral antidiabetic agents work in various ways to reduce blood sugar levels in people with type-2 diabetes; some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals.

There have been constant innovations and studies relating to drug molecules or formulation technologies. For instance, Hanmi Pharmaceutical announced in September 2021 that its new, long-acting diabetes biologic drug, efpeglenatide (GLP-1 RA), was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the results of its global, large-scale clinical trial with more than 4,000 patients, adding to the efficacy of the drug.

In July 2022, the Saudi Government announced that Saudi Arabia saw growing demand for quality healthcare services, spurred by changes including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.

Owing to the aforementioned factors, the market is expected to grow during the forecast period.

Middle East and Africa Diabetes Drugs Market, Volume CAGR (%), by Geography, 2023-2028

MEA Diabetes Drugs Industry Overview

The Middle East and African diabetes drugs market is moderately fragmented, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, etc., holding a presence in the region and other regional players. A major share of the market is held by manufacturers, concomitant with strategy-based M&A operations, and constantly entering the market to generate new revenue streams and boost existing ones. These measures taken by the market players are expected to ensure a competitive marketplace, therefore forcing the companies to experiment with more new technologies.

MEA Diabetes Drugs Market Leaders

  1. Boehringer Ingelheim

  2. Astrazeneca

  3. Eli Lilly

  4. Sanofi

  5. Novo Nordisk

*Disclaimer: Major Players sorted in no particular order

MEA Diabetes Drugs Market Concentration

MEA Diabetes Drugs Market News

  • July 2022: Novo Nordisk launched the first-ever oral GLP-1 RA medicine to control blood glucose for type-2 diabetes patients. The Saudi Food and Drug Authority certified it, and it is now in use throughout the Kingdom and the Arab world. The company mentioned, "The treatment of GLP-1 RA has been on the market a long time ago in injection form, but our team created this innovative pill to help patients with diabetes have a normal lifestyle."
  • June 2022: Gulf Pharmaceutical Industries (Julphar) and Hangzhou Zhongmei Huadong Pharmaceutical Co. announced strategic cooperation to develop, manufacture, and commercialize Liraglutide (including both indications of diabetes and obesity) in 17 countries in the Middle East and North Africa region (MENA), including the UAE.

MEA Diabetes Drugs Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Oral Anti-diabetic Drugs

      1. 5.1.1 Biguanides

        1. Metformin

      2. 5.1.2 Alpha - Glucosidase Inhibitors

        1. Alpha - Glucosidase Inhibitors

      3. 5.1.3 Dopamine -D2 Receptor Agonist

        1. Bromocriptin (Cycloset)

      4. 5.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor

        1. Invokana (Canagliflozin)

        2. Jardiance (Empagliflozin)

        3. Farxiga/Forxiga (Dapagliflozin)

        4. Suglat (Ipragliflozin)

      5. 5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors

        1. Januvia (Sitagliptin)

        2. Onglyza (Saxagliptin)

        3. Tradjenta (Linagliptin)

        4. Vipidia/Nesina (Alogliptin)

        5. Galvus (Vildagliptin)

      6. 5.1.6 Sulfonylureas

        1. Sulfonylureas

      7. 5.1.7 Meglitinides

        1. Meglitinides

    2. 5.2 Insulins

      1. 5.2.1 Basal or Long Acting Insulins

        1. Lantus (Insulin Glargine)

        2. Levemir (Insulin Detemir)

        3. Toujeo (Insulin Glargine)

        4. Tresiba (Insulin Degludec)

        5. Basaglar (Insulin Glargine)

      2. 5.2.2 Bolus or Fast Acting Insulins

        1. NovoRapid/Novolog (Insulin Aspart)

        2. Humalog (Insulin Lispro)

        3. Apidra (Insulin Glulisine)

      3. 5.2.3 Traditional Human Insulins

        1. Novolin/Actrapid/Insulatard

        2. Humulin

        3. Insuman

      4. 5.2.4 Biosimilar Insulins

        1. Insulin Glargine Biosimilars

        2. Human Insulin Biosimilars

    3. 5.3 Combination drugs

      1. 5.3.1 Insulin combinations

        1. NovoMix (Biphasic Insulin Aspart)

        2. Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. Xultophy (Insulin Degludec and Liraglutide)

      2. 5.3.2 Oral Combinations

        1. Janumet (Sitagliptin and Metformin)

    4. 5.4 Non-Insulin Injectable drugs

      1. 5.4.1 GLP-1 receptor agonists

        1. Victoza (Liraglutide)

        2. Byetta (Exenatide)

        3. Bydureon (Exenatide)

        4. Trulicity (Dulaglutide)

        5. Lyxumia (Lixisenatide)

      2. 5.4.2 Amylin Analogue

        1. Symlin (Pramlintide)

    5. 5.5 Geography

      1. 5.5.1 Saudi Arabia

      2. 5.5.2 Iran

      3. 5.5.3 Egypt

      4. 5.5.4 Oman

      5. 5.5.5 South Africa

      6. 5.5.6 Rest of Middle East and Africa


    1. 6.1 Type-1 Diabetic Population

    2. 6.2 Type-2 Diabetic Population



      1. 7.1.1 Novo Nordisk AS

      2. 7.1.2 Takeda

      3. 7.1.3 Pfizer

      4. 7.1.4 Eli Lilly

      5. 7.1.5 Janssen Pharmaceuticals

      6. 7.1.6 Astellas

      7. 7.1.7 Boehringer Ingelheim

      8. 7.1.8 Merck and Co.

      9. 7.1.9 AstraZeneca

      10. 7.1.10 Bristol Myers Squibb

      11. 7.1.11 Novartis

      12. 7.1.12 Sanofi Aventis

    2. *List Not Exhaustive

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 AstraZeneca

      5. 7.2.5 Janssen Pharmaceuticals

      6. 7.2.6 Merck and Co.

      7. 7.2.7 Others


**Subject to Availability
*The report covers a segment-wise breakdown (Value and Volume) for all the countries covered under Table of Contents **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

MEA Diabetes Drugs Market Research FAQs

The Middle East and Africa Diabetes Drugs Market is studied from 2017 - 2028.

The Middle East and Africa Diabetes Drugs Market is growing at a CAGR of 6.6% over the next 5 years.

The Middle East and Africa Diabetes Drugs Market is valued at 4782 Million USD in 2017.

The Middle East and Africa Diabetes Drugs Market is valued at 6588 Million USD in 2028.

Boehringer Ingelheim, Astrazeneca, Eli Lilly, Sanofi, Novo Nordisk are the major companies operating in Middle East and Africa Diabetes Drugs Market.

MEA Diabetes Drugs Industry Report

Statistics for the 2023 MEA Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. MEA Diabetes Drugs analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!